Novo Nordisk And Hengrui Pharma Sign Exclusive Licence Deal For Once-Weekly Oral GLP-1/GIP Drug HRS-1596, Worth Up To $2.60B
Includes $300M Upfront Payment And Sales Royalties - Novo Gains Exclusive Global Rights Excluding China, Hong Kong, Macao And Taiwan - Hengrui Approved To Begin Phase 1 Trials In China
Story updates
04:41:10 AM UTC
SquawkNews
Novo Nordisk signed an exclusive license deal with Hengrui Pharma for HRS-1596, a phase 1-ready once-weekly oral GLP-1/GIP agonist. Novo secured global rights excluding mainland China, Hong Kong, Macao, Taiwan; terms include USD 300 million upfront. Total potential value reaches USD 2.6 billion tied to milestones; Hengrui also earns royalties on net sales in licensed markets. Program targets obesity, type 2 diabetes; Hengrui has China clearance to start phase 1 trials for weight management. Closing expected in Q4 2026, subject to U.S. antitrust clearance and customary conditions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein. (C)